Posts tagged with turbulent times

Nomura Maintains Buy Rating On Kansai Nerolac
May 2020 , by in ALLIED

In the near term, the brokerage firm Nomura believes the company, with its strong R&D, will launch new products with health-protective features to drive higher-than-industry sales. Kansai Nerolac’s fourth quarter results were below estimates, largely impacted due to the Covid-19 related loc... Read more...

Loading...